On March 26, the FDA approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.